MA-EVERBRIDGE
Everbridge , Inc. (NASDAQ:EVBG), the global leader in critical event management (CEM ), today announced a new comprehensive software-based solution enabled by the Everbridge CEM platform to help businesses , healthcare facilities and governments automate contact tracing initiatives, keep their employees and citizens safe, and facilitate the return to work, all while safeguarding privacy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005339/en/
The Everbridge solution represents the digital transformation of contact tracing when compared to existing approaches which tend to fall into two more-limited categories: highly manual human calling supported by case management tools, or one of a variety of standalone opt-in-based mobile apps. The Everbridge COVID-19 Shield : Contact Tracing solution represents a fundamental paradigm shift for corporate, government and healthcare organizations to more safely return people to work with a faster, more accurate, less costly approach, that also safeguards individual privacy. Everbridge’s intelligent software-based automation can supplement or complement existing manual contact tracing efforts to improve accuracy and speed while reducing cost. Unlike other contact tracing solutions, Everbridge’s multi-faceted approach triangulates multiple sources of data to provide more comprehensive information in a timely manner.
As the Centers for Disease Control and Prevention published recently : “Identifying contacts and ensuring they do not interact with others is critical to protect communities from further spread. If communities are unable to effectively isolate patients and ensure contacts can separate themselves from others, rapid community spread of COVID-19 is likely to increase to the point that strict mitigation strategies will again be needed to contain the virus… Technology partners are key in the modification of existing systems and the development of new user-friendly data interfaces to manage multiple data streams with seamless interoperability.”
Leveraging its market-leading CEM capabilities , Everbridge provides organizations with the industry’s only end-to-end contact tracing solution that combines an existing mobile app for wellness checks and self-reporting combined with pre-existing integrations of company systems to compile a more complete set of actionable information. The mobile app enables individuals to track their symptoms and status with regular wellness checks. When necessary, the system can quickly identify other workers who have been exposed to the virus and communicate the appropriate isolation protocols in an automated manner. As a result, organizations will be able to: leverage a less expensive solution for shortening the cycle time of contact tracing and reducing the possibility of exposure; increase confidence among employees as they reintegrate into work; decrease compliance liability while providing a full audit trail; and maintain individual privacy.
“As the global leader in critical event management to help mitigate COVID-19, Everbridge offers the industry’s most comprehensive path for organizations to help people return to work and other public spaces,” said Imad Mouline, Chief Technology Officer at Everbridge. “With the benefit of thousands of trusted sources of data and our advanced IoT capabilities, we are in a unique position to help organizations automate the coronavirus exposure tracking process, bringing people back safely and helping to recover their operations.”
Drawing on over 225 out-of-the-box integrations , the Everbridge contact tracing solution uses data from physical badge access control systems, Wi-Fi hot spots, calendaring systems, travel itineraries, visitor management, and thermal cameras to determine who may have been exposed to an individual with COVID-19. Bluetooth Low Energy proximity data compiled from digital wayfaring capabilities add information on who was within close proximity; special needs registries help protect the most vulnerable people by highlighting if they have been near an infection; real-time risk intelligence based on 22,000 data sources across 175 countries, tracks everything from virus hotspots (including a dedicated coronavirus data feed ) and travel restrictions, to quarantines and states of emergency in order to determine if people are near areas of heightened risk. Crisis management capabilities automate workflows to alert people potentially at risk, and the system as a whole leverages the world’s largest and most scalable mass notification and public warning platform with the ability to reach over 550 million people in more than 200 countries and territories.
Additional Use Cases for Businesses, Government and Healthcare Organizations:
- Track risk of infection based on location, proximity to hot zones and/or recent potential exposure through travel
- Conduct indoor location-based tracing, room occupancy and employee density monitoring, physical distancing detection, and Personal Protective Equipment (PPE) compliance assessment
- Collect accurate data by combining always-on proximity reporting with opt-in polling from employees via their mobile devices
- Use Everbridge mobile app to help guide patients’ indoor movement, including the Direct to Navigate feature for COVID-19 positive patients, and the Wayfinder feature for all other patients, thereby reducing the risk of contagion
- Help support resumption of surgeries that had been put on hold due to the pandemic
Everbridge Commitment to Security, Compliance and Privacy
The Everbridge software solution keeps track of multiple layers of compliance guidelines at the city, state and federal levels that are dynamically changing. Everbridge adheres to strict privacy policies and has achieved critical security certifications such as ISO 27001, SSAE18 SOC 2/SOC 3, FedRAMP (Federal Risk and Authorization Management Program), Cloud Computing Compliance Controls Catalogue (C5) , all of which underlines the commitment of Everbridge to growing its presence around the world and ensuring that it always operates at market-leading standards .
For interest in learning more about this global Everbridge COVID-19 Shield: Contact Tracing offering, please visit https://www.everbridge.com/ .
As the global leader in critical event management and public warning, Everbridge and its platform reach over 550 million people across the world while serving leading Fortune 500 companies as well as cities , states , and entire countries .
Everbridge will be hosting its “Coronavirus: the Road to Recovery ” virtual leadership summit this week, taking place May 20-21. The conference will feature two marquee keynote speakers: General Colin L. Powell, USA (Ret.), who will speak about leadership in challenging times, and Scott Gottlieb, M.D., former FDA Commissioner, who will discuss a roadmap to recovery. The two-day summit will feature over 15 sessions including “Return to Work: Contact Tracing and Beyond,” presented by Everbridge Chief Technology Officer Imad Mouline. To register and learn more, go to Coronavirus: the Road to Recovery .
About Everbridge
Everbridge , Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order to keep people safe and businesses running. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,200 global customers rely on the company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. The company’s platform sent over 3.5 billion messages in 2019 and offers the ability to reach over 550 million people in more than 200 countries and territories, including the entire mobile populations on a country-wide scale in Australia, Greece, Iceland, the Netherlands, New Zealand, Peru, Singapore, Sweden, and a number of the largest states in India. The company’s critical communications and enterprise safety applications include Mass Notification, Incident Management, Safety Connection™, IT Alerting, Visual Command Center®, Public Warning, Crisis Management, Community Engagement™ and Secure Messaging. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global auto makers, all 4 of the largest global accounting firms, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston and Los Angeles with additional offices in Lansing, San Francisco, Abu Dhabi, Beijing, Bangalore, Kolkata, London, Munich, New York, Oslo, Singapore, Stockholm and Tilburg. For more information, visit www.everbridge.com , read the company blog , and follow on LinkedIn , Twitter , and Facebook .
Cautionary Language Concerning Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005339/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
